Sulfated sugars in the extracellular matrix orchestrate ovarian cancer development: 'When sweet turns sour'

Gynecologic Oncology

Volumn 135, Issue 2, 2014, Pages 371-381

  Vallen, Myrtille J E ^a,b   Van Der Steen, Sophieke C H A ^a,b   Van Tilborg, Angela A G ^b   Massuger, Leon F A G ^b   Van Kuppevelt, Toin H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Carcinogenesis; Chondroitin sulfate; Glycosaminoglycans; Therapeutic targeting

Indexed keywords

CHONDROITIN SULFATE; PROTEOGLYCAN; GLYCOSAMINOGLYCAN;

BIOSYNTHESIS; CANCER GROWTH; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; METASTASIS; NONHUMAN; OVARY CANCER; PROTEIN DEGRADATION; PROTEIN TARGETING; REVIEW; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; CELL MOTION; FEMALE; IMMUNOLOGY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; TUMOR ESCAPE;

CARCINOGENESIS; CELL ADHESION; CELL MOVEMENT; CHONDROITIN SULFATES; EXTRACELLULAR MATRIX; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; TUMOR ESCAPE;

EID: 84914103860     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.08.023     Document Type: Review

References (89)

1. A. Jemal, F. Bray, M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. Ovarian cancer, five-year stage-specific relative survival rates (2004-2008) J Natl Cancer Inst 103 2011 1287
3. R. Chekerov, I. Braicu, D.C. Castillo-Tong, R. Richter, I. Cadron, and S. Mahner Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD Int J Gynecol Cancer 23 2013 268 275
4. M.J. Bissell, D.C. Radisky, A. Rizki, V.M. Weaver, and O.W. Petersen The organizing principle: microenvironmental influences in the normal and malignant breast Differentiation 70 2002 537 546
5. A. Labiche, N. Heutte, P. Herlin, J. Chasle, P. Gauduchon, and N. Elie Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma Int J Gynecol Cancer 20 2010 28 33
6. P. Pothacharoen, S. Siriaunkgul, S. Ong-Chai, J. Supabandhu, P. Kumja, and C. Wanaphirak Raised serum chondroitin sulfate epitope level in ovarian epithelial cancer J Biochem 140 2006 517 524
7. M.J. Vallen, L.F. Massuger, G.B. ten Dam, J. Bulten, and T.H. van Kuppevelt Highly sulfated chondroitin sulfates, a novel class of prognostic biomarkers in ovarian cancer tissue Gynecol Oncol 127 2012 202 209
8. J.D. Esko, K. Kimata, and U. Lindahl A. Varki, R.D. Cummings, J.D. Esko, H.H. Freeze, P. Stanley, C.R. Bertozzi, G.W. Hart, M.E. Etzler, Proteoglycans and sulfated glycosaminoglycans 2009 The Consortium of Glycobiology Editors Cold Spring Harbor NY [La Jolla, California, p.]
9. N. Afratis, C. Gialeli, D. Nikitovic, T. Tsegenidis, E. Karousou, and A.D. Theocharis Glycosaminoglycans: key players in cancer cell biology and treatment FEBS J 279 2012 1177 1197
10. P.A. Kenny, and M.J. Bissell Tumor reversion: correction of malignant behavior by microenvironmental cues Int J Cancer 107 2003 688 695
11. M.S. Pavao, A.C. Vilela-Silva, and P.A. Mourao Biosynthesis of chondroitin sulfate: from the early, precursor discoveries to nowadays, genetics approaches Adv Pharmacol 53 2006 117 140
12. H. Kawashima, K. Atarashi, M. Hirose, J. Hirose, S. Yamada, and K. Sugahara Oversulfated chondroitin/dermatan sulfates containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines J Biol Chem 277 2002 12921 12930
13. M. Stylianou, I.E. Triantaphyllidou, and D.H. Vynios Advances in the analysis of chondroitin/dermatan sulfate Adv Pharmacol 53 2006 141 166
14. S. Ghosh, L. Albitar, R. LeBaron, W.R. Welch, G. Samimi, and M.J. Birrer Up-regulation of stromal versican expression in advanced stage serous ovarian cancer Gynecol Oncol 119 2010 114 120
15. G.B. Ten Dam, E.M. van de Westerlo, A. Purushothaman, R.V. Stan, J. Bulten, and F.C. Sweep Antibody GD3G7 selected against embryonic glycosaminoglycans defines chondroitin sulfate-E domains highly up-regulated in ovarian cancer and involved in vascular endothelial growth factor binding Am J Pathol 171 2007 1324 1333
16. T. Mikami, and H. Kitagawa Biosynthesis and function of chondroitin sulfate Biochim Biophys Acta 1830 2013 4719 4733 10.1016/j.bbagen.2013.4706.4006 [Epub 2013 Jun 4714]
17. E.M. Denholm, Y.Q. Lin, and P.J. Silver Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion Eur J Pharmacol 416 2001 213 221
18. D. Kalathas, D.A. Theocharis, D. Bounias, D. Kyriakopoulou, N. Papageorgakopoulou, and M.S. Stavropoulos Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer Mol Med Rep 4 2011 363 368
19. F. Li, G.B. Ten Dam, S. Murugan, S. Yamada, T. Hashiguchi, and S. Mizumoto Involvement of highly sulfated chondroitin sulfate in the metastasis of the Lewis lung carcinoma cells J Biol Chem 283 2008 34294 34304
20. C.A. Cooney, F. Jousheghany, A. Yao-Borengasser, B. Phanavanh, T. Gomes, and A.M. Kieber-Emmons Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells Breast Cancer Res 13 2011 R58
21. L. Dubeau The cell of origin of ovarian epithelial tumours Lancet Oncol 9 2008 1191 1197
22. D.W. Kindelberger, Y. Lee, A. Miron, M.S. Hirsch, C. Feltmate, and F. Medeiros Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship Am J Surg Pathol 31 2007 161 169
23. I. Skirnisdottir, T. Seidal, E. Gerdin, and B. Sorbe The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy Int J Gynecol Cancer 12 2002 265 276
24. Y.H. Teng, P.H. Tan, S.J. Chia, N.A. Zam, W.K. Lau, and C.W. Cheng Increased expression of non-sulfated chondroitin correlates with adverse clinicopathological parameters in prostate cancer Mod Pathol 21 2008 893 901 10.1038/modpathol.2008.1070 [Epub 2008 May 1016]
25. H. Lv, G. Yu, L. Sun, Z. Zhang, X. Zhao, and W. Chai Elevate level of glycosaminoglycans and altered sulfation pattern of chondroitin sulfate are associated with differentiation status and histological type of human primary hepatic carcinoma Oncology 72 2007 347 356
26. S. Mizumoto, M. Watanabe, S. Yamada, and K. Sugahara Expression of N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase involved in chondroitin sulfate synthesis is responsible for pulmonary metastasis BioMed Res Int 2013 2013 656319
27. T. Kobayashi, H. Yan, Y. Kurahashi, Y. Ito, H. Maeda, and T. Tada Role of GalNAc4S-6ST in astrocytic tumor progression PLoS One 8 2013 e54278
28. H. Yoon, S. Liyanarachchi, F.A. Wright, R. Davuluri, J.C. Lockman, and A. de la Chapelle Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 Proc Natl Acad Sci U S A 99 2002 15632 15637
29. K. Munstedt, G.R. von, and F.E. Franke Correlation between MIB1-determined tumor growth fraction and incidence of tumor recurrence in early ovarian carcinomas Cancer Invest 22 2004 185 194
30. S. Mizumoto, D. Fongmoon, and K. Sugahara Interaction of chondroitin sulfate and dermatan sulfate from various biological sources with heparin-binding growth factors and cytokines Glycoconj J 30 2013 619 632 10.1007/s10719-10012-19463-10715 [Epub 12012 Dec 10729]
31. D. Nikitovic, A. Zafiropoulos, G.N. Tzanakakis, N.K. Karamanos, and A.M. Tsatsakis Effects of glycosaminoglycans on cell proliferation of normal osteoblasts and human osteosarcoma cells depend on their type and fine chemical compositions Anticancer Res 25 2005 2851 2856
32. C.D. Nandini, and K. Sugahara Role of the sulfation pattern of chondroitin sulfate in its biological activities and in the binding of growth factors Adv Pharmacol 53 2006 253 279
33. A.J. Yee, M. Akens, B.L. Yang, J. Finkelstein, P.S. Zheng, and Z. Deng The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis Breast Cancer Res 9 2007 R47
34. Y. Zhang, L. Cao, B.L. Yang, and B.B. Yang The G3 domain of versican enhances cell proliferation via epidermal growth factor-like motifs J Biol Chem 273 1998 21342 21351
35. S.B. Coffelt, R.S. Waterman, L. Florez, K. Honer zu Bentrup, K.J. Zwezdaryk, and S.L. Tomchuck Ovarian cancers overexpress the antimicrobial protein hCAP-18 and its derivative LL-37 increases ovarian cancer cell proliferation and invasion Int J Cancer 122 2008 1030 1039
36. D. Li, X. Wang, J.L. Wu, W.Q. Quan, L. Ma, and F. Yang Tumor-produced versican v1 enhances hCAP18/LL-37 expression in macrophages through activation of TLR2 and vitamin D3 signaling to promote ovarian cancer progression in vitro PLoS One 8 2013 e56616
37. S.B. Coffelt, F.C. Marini, K. Watson, K.J. Zwezdaryk, J.L. Dembinski, and H.L. LaMarca The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells Proc Natl Acad Sci U S A 106 2009 3806 3811
38. M.A. Nash, A.E. Loercher, and R.S. Freedman In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin Cancer Res 59 1999 6192 6196
39. A. Hildebrand, M. Romaris, L.M. Rasmussen, D. Heinegard, D.R. Twardzik, and W.A. Border Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta Biochem J 302 Pt 2 1994 527 534
40. A. De Luca, M. Santra, A. Baldi, A. Giordano, and R.V. Iozzo Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases J Biol Chem 271 1996 18961 18965
41. R.V. Iozzo, and R.D. Sandersonb Proteoglycans in cancer biology, tumor microenvironment and angiogenesis J Cell Mol Med 5 2011 1013 1031
42. M.A. Nash, M.T. Deavers, and R.S. Freedman The expression of decorin in human ovarian tumors Clin Cancer Res 8 2002 1754 1760
43. T.R. Newton, P.G. Parsons, D.J. Lincoln, M.C. Cummings, D.K. Wyld, and P.M. Webb Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer Int J Cancer 119 2006 875 883
44. J. Folkman, K. Watson, D. Ingber, and D. Hanahan Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 1989 58 61
45. S.M. Weis, and D.A. Cheresh Tumor angiogenesis: molecular pathways and therapeutic targets Nat Med 17 2011 1359 1370
46. R.A. Burger Overview of anti-angiogenic agents in development for ovarian cancer Gynecol Oncol 121 2011 230 238
47. Y. Liu, H. Yang, K. Otaka, H. Takatsuki, and A. Sakanishi Effects of vascular endothelial growth factor (VEGF) and chondroitin sulfate A on human monocytic THP-1 cell migration Colloids Surf B: Biointerfaces 43 2005 216 220
48. E. Fthenou, A. Zafiropoulos, A. Tsatsakis, A. Stathopoulos, N.K. Karamanos, and G.N. Tzanakakis Chondroitin sulfate A chains enhance platelet derived growth factor-mediated signalling in fibrosarcoma cells Int J Biochem Cell Biol 38 2006 2141 2150
49. S. Cattaruzza, M. Schiappacassi, A. Ljungberg-Rose, P. Spessotto, D. Perissinotto, and M. Morgelin Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro J Biol Chem 277 2002 47626 47635
50. P.S. Zheng, J. Wen, L.C. Ang, W. Sheng, A. Viloria-Petit, and Y. Wang Versican/PG-MG3 domain promotes tumor growth and angiogenesis FASEB J 18 2004 754 756
51. Y. Fu, J.A. Nagy, L.F. Brown, S.C. Shih, P.Y. Johnson, and C.K. Chan Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis J Histochem Cytochem 59 2011 463 473
52. T. Neill, H. Painter, S. Buraschi, R.T. Owens, M.P. Lisanti, and L. Schaefer Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3 J Biol Chem 287 2012 5492 5506
53. D. Gao, L.T. Vahdat, S. Wong, J.C. Chang, and V. Mittal Microenvironmental regulation of epithelial-mesenchymal transitions in cancer Cancer Res 72 2012 4883 4889
54. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial-mesenchymal transitions in development and disease Cell 139 2009 871 890
55. W. Sheng, G. Wang, D.P. La Pierre, J. Wen, Z. Deng, and C.K. Wong Versican mediates mesenchymal-epithelial transition Mol Biol Cell 17 2006 2009 2020
56. T. Koike, T. Izumikawa, J. Tamura, and H. Kitagawa Chondroitin sulfate-E fine-tunes osteoblast differentiation via ERK1/2, Smad3 and Smad1/5/8 signaling by binding to N-cadherin and cadherin-11 Biochem Biophys Res Commun 420 2012 523 529 10.1016/j.bbrc.2012.1003.1024 [Epub 2012 Mar 1013]
57. R.C. Casey, T.R. Oegema Jr., K.M. Skubitz, S.E. Pambuccian, S.M. Grindle, and A.P. Skubitz Cell membrane glycosylation mediates the adhesion, migration, and invasion of ovarian carcinoma cells Clin Exp Metastasis 20 2003 143 152
58. W.L. Gu, S.L. Fu, Y.X. Wang, Y. Li, H.Z. Lu, and X.M. Xu Chondroitin sulfate proteoglycans regulate the growth, differentiation and migration of multipotent neural precursor cells through the integrin signaling pathway BMC Neurosci 10 2009 128 10.1186/1471-2202-1110-1128
59. J. Iida, A.M. Meijne, J.R. Knutson, L.T. Furcht, and J.B. McCarthy Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion Semin Cancer Biol 7 1996 155 162
60. R. Kokenyesi Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix J Cell Biochem 83 2001 259 270
61. J.B. Catterall, L.M. Jones, and G.A. Turner Membrane protein glycosylation and CD44 content in the adhesion of human ovarian cancer cells to hyaluronan Clin Exp Metastasis 17 1999 583 591
62. S. Georges, D. Heymann, and M. Padrines Modulatory effects of proteoglycans on proteinase activities Methods Mol Biol 836 2012 307 322 10.1007/1978-1001-61779-61498-61778-61720
63. T. Murai, Y. Miyazaki, H. Nishinakamura, K.N. Sugahara, T. Miyauchi, and Y. Sako Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration J Biol Chem 279 2004 4541 4550 [Epub 2003 Nov 4517]
64. N. Suenaga, H. Mori, Y. Itoh, and M. Seiki CD44 binding through the hemopexin-like domain is critical for its shedding by membrane-type 1 matrix metalloproteinase Oncogene 24 2005 859 868
65. W.H. Yu, J.F. Woessner Jr., J.D. McNeish, and I. Stamenkovic CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling Genes Dev 16 2002 307 323
66. R.D. Prinz, C.M. Willis, A. Viloria-Petit, and M. Kluppel Elimination of breast tumor-associated chondroitin sulfate promotes metastasis Genet Mol Res 10 2011 3901 3913
67. J. Takeuchi Effect of chondroitinases on the growth of solid Ehrlich ascites tumour Br J Cancer 26 1972 115 119
68. R. Yigit, L.F. Massuger, C.G. Figdor, and R. Torensma Ovarian cancer creates a suppressive microenvironment to escape immune elimination Gynecol Oncol 117 2010 366 372
69. S. Singh, S.R. Ross, M. Acena, D.A. Rowley, and H. Schreiber Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells J Exp Med 175 1992 139 146
70. A.E. Proudfoot The biological relevance of chemokine-proteoglycan interactions Biochem Soc Trans 34 2006 422 426
71. N. Said, M. Sanchez-Carbayo, S.C. Smith, and D. Theodorescu RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration J Clin Invest 122 2012 1503 1518
72. S. Sakai, H. Akiyama, N. Harikai, H. Toyoda, T. Toida, and T. Maitani Effect of chondroitin sulfate on murine splenocytes sensitized with ovalbumin Immunol Lett 84 2002 211 216
73. H. Akiyama, S. Sakai, R.J. Linhardt, Y. Goda, T. Toida, and T. Maitani Chondroitin sulphate structure affects its immunological activities on murine splenocytes sensitized with ovalbumin Biochem J 382 2004 269 278
74. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
75. A.E. Faassen, D.L. Mooradian, R.T. Tranquillo, R.B. Dickinson, P.C. Letourneau, and T.R. Oegema Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-beta-stimulated mouse melanoma cell motility and invasive behavior on type I collagen J Cell Sci 105 Pt 2 1993 501 511
76. M. Chekenya, C. Krakstad, A. Svendsen, I.A. Netland, V. Staalesen, and B.B. Tysnes The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling Oncogene 27 2008 5182 5194
77. J. Wang, A. Svendsen, J. Kmiecik, H. Immervoll, K.O. Skaftnesmo, and J. Planaguma Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma PLoS One 6 2011 e23062
78. J.S. Wall, T. Richey, A. Stuckey, R. Donnell, A. Oosterhof, and T.H. van Kuppevelt SPECT imaging of peripheral amyloid in mice by targeting hyper-sulfated heparan sulfate proteoglycans with specific scFv antibodies Nucl Med Biol 39 2012 65 75 10.1016/j.nucmedbio.2011.1006.1007 [Epub 2011 Sep 1029]
79. X. Wang, T. Osada, Y. Wang, L. Yu, K. Sakakura, and A. Katayama CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer J Natl Cancer Inst 102 2010 1496 1512
80. Z. Rivera, S. Ferrone, X. Wang, S. Jube, H. Yang, and H.I. Pass CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma Clin Cancer Res 18 2012 5352 5363
81. T.J. Perren, A.M. Swart, J. Pfisterer, J.A. Ledermann, E. Pujade-Lauraine, and G. Kristensen A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
82. W.H. Gotlieb, F. Amant, S. Advani, C. Goswami, H. Hirte, and D. Provencher Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study Lancet Oncol 13 2012 154 162 10.1016/S1470-2045(1011)70338-70332 [Epub 72011 Dec 70320]
83. S. Goldoni, D.G. Seidler, J. Heath, M. Fassan, R. Baffa, and M.L. Thakur An antimetastatic role for decorin in breast cancer Am J Pathol 173 2008 844 855
84. D.S. Grant, C. Yenisey, R.W. Rose, M. Tootell, M. Santra, and R.V. Iozzo Decorin suppresses tumor cell-mediated angiogenesis Oncogene 21 2002 4765 4777
85. C.M. Lee, T. Tanaka, T. Murai, M. Kondo, J. Kimura, and W. Su Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo Cancer Res 62 2002 4282 4288
86. M. de Bruyn, A.A. Rybczynska, Y. Wei, M. Schwenkert, G.H. Fey, and R.A. Dierckx Melanoma-associated chondroitin sulfate proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo Mol Cancer 9 2010 301
87. X. Wang, A. Katayama, Y. Wang, L. Yu, E. Favoino, and K. Sakakura Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4 Cancer Res 71 2011 7410 7422
88. R. Noguera, O.A. Nieto, I. Tadeo, F. Farinas, and T. Alvaro Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview Histol Histopathol 27 2012 693 705
89. C.Y. Pumphrey, A.M. Theus, S. Li, R.S. Parrish, and R.D. Sanderson Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis Cancer Res 62 2002 3722 3728